NEW YORK, Nov. 17 (GenomeWeb News) - Iconix Pharmaceuticals has licensed its DrugMatrix chemogenomics system and Drug Signatures library to Elli Lilly and renewed a deal with the US Food and Drug Administration for the DrugMatrix system, the firm said today.
Under the agreement with Lilly, Iconix will add new compounds and tissues to DrugMatrix and identify additional Drug Signatures for those new domains. Lilly will integrate its in-house toxicogenomics data with DrugMatrix.
The agreement is similar to ones Iconix has in place with Bristol-Myers Squibb and Abbott.
Under the deal with the FDA, the agency's Center for Drug Evaluation and Research renewed its DrugMatrix agreement. The FDA installed DrugMatrix originally in March 2003 to use genomic markers to profile drug effects.
Under the renewal, Iconix will provide DrugMatrix to the FDA's Interdisciplinary Pharmacogenomic Review Group to evaluate genomic data submitted under the new data submission guidelines.